A tumorigenicity evaluation platform for cell therapies based on brain organoids.

Publisher: BioMed Central Country of Publication: England NLM ID: 101591861 Publication Model: Electronic Cited Medium: Print ISSN: 2047-9158 (Print) Linking ISSN: 20479158 NLM ISO Abbreviation: Transl Neurodegener Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2012-

Organoids* ; Mice, SCID* ; Pluripotent Stem Cells* ; Brain Neoplasms*/therapy ; Brain Neoplasms*/genetics ; Brain Neoplasms*/pathology ; Brain Neoplasms*/metabolism ; Mice, Inbred NOD*; Animals ; Humans ; Mice ; Glioblastoma/therapy ; Glioblastoma/pathology ; Glioblastoma/genetics ; Glioblastoma/metabolism ; Brain/pathology ; Brain/metabolism ; Carcinogenesis/genetics ; Cell- and Tissue-Based Therapy/methods ; Cell- and Tissue-Based Therapy/trends

Background: Tumorigenicity represents a critical challenge in stem cell-based therapies requiring rigorous monitoring. Conventional approaches for tumorigenicity evaluation are based on animal models and have numerous limitations. Brain organoids, which recapitulate the structural and functional complexity of the human brain, have been widely used in neuroscience research. However, the capacity of brain organoids for tumorigenicity evaluation needs to be further elucidated.
Methods: A cerebral organoid model produced from human pluripotent stem cells (hPSCs) was employed. Meanwhile, to enhance the detection sensitivity for potential tumorigenic cells, we created a glioblastoma-like organoid (GBM organoid) model from TP53 ^-/- /PTEN ^-/- hPSCs to provide a tumor microenvironment for injected cells. Midbrain dopamine (mDA) cells from human embryonic stem cells were utilized as a cell therapy product. mDA cells, hPSCs, mDA cells spiked with hPSCs, and immature mDA cells were then injected into the brain organoids and NOD SCID mice. The injected cells within the brain organoids were characterized, and compared with those injected in vivo to evaluate the capability of the brain organoids for tumorigenicity evaluation. Single-cell RNA sequencing was performed to identify the differential gene expression between the cerebral organoids and the GBM organoids.
Results: Both cerebral organoids and GBM organoids supported maturation of the injected mDA cells. The hPSCs and immature mDA cells injected in the GBM organoids showed a significantly higher proliferative capacity than those injected in the cerebral organoids and in NOD SCID mice. Furthermore, the spiked hPSCs were detectable in both the cerebral organoids and the GBM organoids. Notably, the GBM organoids demonstrated a superior capacity to enhance proliferation and pluripotency of spiked hPSCs compared to the cerebral organoids and the mouse model. Kyoto Encyclopedia of Genes and Genomes analysis revealed upregulation of tumor-related metabolic pathways and cytokines in the GBM organoids, suggesting that these factors underlie the high detection sensitivity for tumorigenicity evaluation.
Conclusions: Our findings suggest that brain organoids could represent a novel and effective platform for evaluating the tumorigenic risk in stem cell-based therapies. Notably, the GBM organoids offer a superior platform that could complement or potentially replace traditional animal-based models for tumorigenicity evaluation.
(© 2024. The Author(s).)

PLoS Med. 2009 Feb 17;6(2):e1000029. (PMID: 19226183)
Stem Cells. 2012 May;30(5):935-45. (PMID: 22328536)
Cell Stem Cell. 2023 Oct 5;30(10):1299-1314.e9. (PMID: 37802036)
BMJ. 2010 Oct 12;341:c5724. (PMID: 20940208)
Development. 2019 Apr 16;146(8):. (PMID: 30992274)
Cytokine Growth Factor Rev. 2024 Apr;76:12-21. (PMID: 38431507)
NPJ Precis Oncol. 2024 Jan 26;8(1):19. (PMID: 38273014)
J Clin Invest. 2020 Feb 3;130(2):904-920. (PMID: 31714896)
Cell Death Dis. 2017 Jan 19;8(1):e2568. (PMID: 28102844)
Stem Cells. 2006 Jun;24(6):1433-40. (PMID: 16556709)
Nat Methods. 2023 Dec;20(12):2034-2047. (PMID: 38052989)
Nature. 2019 Oct;574(7778):418-422. (PMID: 31619793)
Nature. 2019 Sep;573(7772):61-68. (PMID: 31435019)
Cell Transplant. 2013;22(7):1263-79. (PMID: 23031199)
Nat Methods. 2015 Jul;12(7):671-8. (PMID: 26005811)
Semin Cell Dev Biol. 2023 Jul 30;144:97-102. (PMID: 35339359)
BMJ. 2010 Nov 16;341:c6574. (PMID: 21081623)
Nature. 2023 Nov;623(7986):397-405. (PMID: 37914940)
Cell. 2022 Jan 6;185(1):42-61. (PMID: 34774127)
Cell Stem Cell. 2016 Feb 4;18(2):174-88. (PMID: 26849304)
Nat Biotechnol. 2020 Dec;38(12):1421-1430. (PMID: 33273741)
J Vis Exp. 2023 Jul 21;(197):. (PMID: 37590518)
Animals (Basel). 2022 Nov 15;12(22):. (PMID: 36428378)
Mol Cancer. 2022 Dec 22;21(1):225. (PMID: 36550571)
Toxicol Appl Pharmacol. 2018 Sep 1;354:40-55. (PMID: 29753005)
Nat Protoc. 2022 Mar;17(3):890-909. (PMID: 35140411)
Nat Protoc. 2014 Oct;9(10):2329-40. (PMID: 25188634)
Ageing Res Rev. 2023 Jan;83:101792. (PMID: 36402405)
Nat Commun. 2020 Jul 6;11(1):3369. (PMID: 32632153)
Oncol Rep. 2009 Dec;22(6):1349-56. (PMID: 19885586)
Nat Rev Clin Oncol. 2022 Apr;19(4):237-253. (PMID: 34997230)
Stem Cells Dev. 2016 Jun 1;25(11):815-25. (PMID: 27059007)
Science. 2016 Jun 24;352(6293):1586-90. (PMID: 27339989)
Nat Neurosci. 2020 Dec;23(12):1496-1508. (PMID: 33139941)
Stem Cell Reports. 2019 Sep 10;13(3):440-447. (PMID: 31509736)
Nature. 2010 Jun 24;465(7301):997. (PMID: 20577182)
Nature. 2013 Sep 19;501(7467):373-9. (PMID: 23995685)
Cell Rep. 2016 Dec 20;17(12):3369-3384. (PMID: 28009303)
Cell Rep. 2019 Mar 19;26(12):3203-3211.e5. (PMID: 30893594)
Stem Cells Dev. 2022 Mar;31(5-6):97-101. (PMID: 35018826)
Cell Stem Cell. 2021 Feb 4;28(2):217-229.e7. (PMID: 33545080)
Elife. 2022 May 04;11:. (PMID: 35506651)
Cell Stem Cell. 2020 Oct 1;27(4):523-531. (PMID: 33007237)
N Engl J Med. 2020 May 14;382(20):1926-1932. (PMID: 32402162)
Nat Rev Nephrol. 2019 Jun;15(6):346-366. (PMID: 30858582)
Nat Commun. 2021 Dec 15;12(1):7302. (PMID: 34911939)
Neuron. 2018 Oct 24;100(2):389-405. (PMID: 30359604)
Science. 2014 Jul 18;345(6194):1247125. (PMID: 25035496)
Cell Stem Cell. 2024 Jan 4;31(1):25-38.e8. (PMID: 38086390)
Nat Protoc. 2018 Mar;13(3):565-580. (PMID: 29470464)
Stem Cell Reports. 2021 Jun 8;16(6):1398-1408. (PMID: 34048692)
Exp Cell Res. 2018 Jan 1;362(1):159-171. (PMID: 29129566)
J Hematol Oncol. 2023 Sep 12;16(1):103. (PMID: 37700339)
Cell Stem Cell. 2023 May 4;30(5):512-529. (PMID: 37084729)
CNS Neurosci Ther. 2023 Oct;29(10):2725-2743. (PMID: 37248629)
Dev Cell. 2021 May 17;56(10):1363-1393. (PMID: 33945792)
Oncogene. 2020 Oct;39(44):6747-6756. (PMID: 32978521)
Cell Stem Cell. 2011 Jun 3;8(6):618-28. (PMID: 21624806)
Nat Med. 2013 Aug;19(8):998-1004. (PMID: 23921754)
Cell Stem Cell. 2016 Aug 4;19(2):248-257. (PMID: 27476966)
Sci Rep. 2016 Sep 30;6:34478. (PMID: 27686862)
Nat Biotechnol. 2018 Jun;36(5):432-441. (PMID: 29658944)
Nat Protoc. 2022 Jan;17(1):15-35. (PMID: 34992269)

82272116 National Natural Science Foundation of China; 2024M750539 China Postdoctoral Science Foundation

Keywords: Brain organoids; Cell therapies; Tumorigenicity evaluation

Date Created: 20241030 Date Completed: 20241030 Latest Revision: 20241101

20250114

PMC11520457

10.1186/s40035-024-00446-5

39472972